Eli Lilly is letting go 340 of its IT personnel as part of a reorganization announced last fall to trim 5,500 jobs. Report

Original Source of Lilly layoffs extend to 340 IT workers

After a recent study suggested that the angiotensin receptor blockers–including Novartis’ Diovan and Merck’s Cozaar –carry an increased risk of cancer, the FDA has decided to follow up on that research with a review of its own. The agency says it’s putting ARBs under a safety review, with plans…

Elan has joined the marketing-settlement club. The Irish drugmaker has agreed to pay $203.5 million to settle U.S. government probes into its sales and marketing tactics on the epilepsy drug Zonegran.

Johnson & Johnson ( NYSE: JNJ )

Sanofi-Aventis is moving work around–and the changes are claiming jobs. As Pharmalot reports, the French drugmaker is shifting laboratory and regulatory affairs work from Great Valley, PA, to other locations, putting 400 employees and 200 contract workers in jeopardy. Meanwhile, a pilot plant in Bridgewater, NJ, is slated for…

Novartis has conceded the fight with its female employees . The Swiss drugmaker agreed to pay up to $175 million to settle a high-profile gender discrimination lawsuit, ending a battle that put Novartis managers’ misbehavior in the headlines.

It’s legal wrap-up week for GlaxoSmithKline. First, the company agreed to settle

The Amgen Foundation is supporting an online competition with Ashoka’s Changemakers to find the best solutions that elevate patients’ voices to improve health outcomes globally.

Original Source of Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients

After two days of deliberation, we saw a mixed vote on Avandia . Twelve members voted to take off the market, while 17 recommended changing the label to various degrees. Three

The clotbuster Effient is one of Eli Lilly’s ( NYSE: LLY ) great new hopes,